Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Nelson

Showing results (481-490 of 521) with videos related to

Pageof 53
Sort By:
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Clinical pharmacogenetics implementation: approaches, successes, and challengesKristin W Weitzel, Amanda R Elsey, Taimour Y Langaee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2016
The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from Siraitia grosvenoriiMaxim Itkin, Rachel Davidovich-Rikanati, Shahar Cohen, et al.
Scientific Reports|March 16, 2016
Insights into Adaptations to a Near-Obligate Nematode Endoparasitic Lifestyle from the Finished Genome of Drechmeria coniosporaLiwen Zhang, Zhengfu Zhou, Qiannan Guo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
The New England Journal of Medicine|January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionMark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.
Elife|October 17, 2018
Firefly genomes illuminate parallel origins of bioluminescence in beetlesTimothy R Fallon, Sarah E Lower, Ching-Ho Chang, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
Pageof 53

Showing results (481-490 of 521) with videos related to

Sort By:
Pageof 53
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Clinical pharmacogenetics implementation: approaches, successes, and challengesKristin W Weitzel, Amanda R Elsey, Taimour Y Langaee, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2016
The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from Siraitia grosvenoriiMaxim Itkin, Rachel Davidovich-Rikanati, Shahar Cohen, et al.
Scientific Reports|March 16, 2016
Insights into Adaptations to a Near-Obligate Nematode Endoparasitic Lifestyle from the Finished Genome of Drechmeria coniosporaLiwen Zhang, Zhengfu Zhou, Qiannan Guo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
The New England Journal of Medicine|January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionMark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.
Elife|October 17, 2018
Firefly genomes illuminate parallel origins of bioluminescence in beetlesTimothy R Fallon, Sarah E Lower, Ching-Ho Chang, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
Pageof 53